nach oben

Drugs in R&D

Erschienen in:

01.11.2003 | Original Research Article

Tissue Storage of ¹⁴C-Labelled Hydroxyethyl Starch (HES) 130/0.4 and HES 200/0.5 after Repeated Intravenous Administration to Rats

verfasst von: Jost Leuschner, Jens Opitz, Andreas Winkler, Roland Scharpf, Dr Frank Bepperling

Erschienen in: Drugs in R&D | Ausgabe 6/2003

Einloggen, um Zugang zu erhalten

Abstract

Objective: To investigate the effect of the molar substitution of hydroxyethyl starch (HES) solutions on tissue and organ storage in rats after repeated administration.

Study design: A controlled, multiple-dose study was performed in 48 rats. Daily bolus injections of 0.7 g/kg of 10% HES 130/0.4 or 10% HES 200/0.5 were administered on 18 consecutive days. In order to examine quantitatively the distribution and excretion of both preparations on HES tissue storage, radiolabelled HES was measured 3, 10, 24 and 52 days after the last administration. Tissue storage was expressed as percentage radioactivity of total administered HES dose in the total body, carcass, liver, kidney, spleen, lymph nodes, plasma and urine.

Results: 52 days after the last administration the remaining radioactivity of labelled HES 200/0.5 was nearly 4-fold higher compared with HES 130/0.4 in the total body (2.45% vs 0.65% of the total administered dose). This difference in tissue storage was statistically significant (p ≤ 0.01). A comparable difference was observed for the liver and carcass.

Conclusion: Tissue storage after repeated administration of an HES solution with a low molar substitution (0.4) was significantly lower in the total body as well as in the liver and carcass compared with an HES solution with a medium molar substitution (0.5). However, the potential clinical consequences of these present findings have not yet been determined.

The use of tradenames is for product identification purposes only and does not imply endorsement.

Treib J, Baron JF, Grauer MT, et al. An international view of hydroxyethyl starches. Intensive Care Med 1999; 25: 258–68PubMedCrossRef

Treib J, Haass A, Pindur G, et al. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995; 78: 1452–6

Mishler JM. Pharmacology of hydroxyethyl starch. New York: Oxford University Press, 1982

Ständer S, Szepfalusi Z, Bohle B, et al. Differential storage of hydroxyethyl starch (HES) in the skin: an immunoelectron-microscopical long-term study. Cell Tissue Res 2001; 304: 261–9PubMedCrossRef

Reimann S, Szepfalusi Z, Kraft D, et al. Hydroxyethylstärke-Speicherung in der Haut unter besonderer Berücksichtigung des Hydroxyethylstärke-assozierten Juckreizes. Dtsch Med Wochenschr 2000; 125: 280–5PubMedCrossRef

Gall H, Kaufmann R, von Ehr M, et al. Persistierender Pruritus nach Hydroxyäthylstärke-Infusionen. Hautarzt 1993; 44: 713–6PubMed

Kiesewetter H, Blume J, Jung F, et al. Haemodilution with medium molecular weight hydroxyethyl starch in patients with peripheral arterial occlusive disease stage IIb. J Intern Med 1990; 227: 107–14PubMedCrossRef

Hulse JD, Yacobi A. Hetastarch: an overview of the colloid and its metabolism. Drug Intell Clin Pharm 1983; 17: 334–41PubMed

Waitzinger J, Bepperling F, Papst G, et al. Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification (HES 130/0.4) after single-dose infusion of 6% or 10% solutions in healthy volunteers. Clin Drug Invest 1998; 16: 151–60CrossRef

10.

Jungheinrich C, Scharpf R, Wargenau M, et al. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500ml) in mild-to-severe renal impairment. Anesth Analg 2002; 95: 544–51PubMed

11.

Waitzinger J, Bepperling F, Pabst G F, et al. Hydroxyethyl starch (HES) [HES 130/0.4], a new specification: pPharmacokinetics and safety of after multiple infusions of 10% solution in healthy volunteers. Drugs R&D 2003; 4: 149–57CrossRef

12.

Asskali F, Forster H. Zur Kumulation unterschiedlich substituierter Hydroxyethylstärke (HES) nach repetetiver Infusion bei gesunden Versuchsprobanden. Anasthesiol Intensivmed Notfallmed Schmerzther 1999; 34: 537–41PubMedCrossRef

13.

Dienes HP, Gerharz CD, Wagner R, et al. Accumulation of hydroxyethyl starch (HES) in the liver of patients with renal failure and portal hypertension. J Hepatol 1986; 3: 223–7PubMedCrossRef

14.

Pfeifer U, Kult J, Forster H. Ascites als Komplikation hepatischer Speicherung von Hydroxyethylstärke (HES) nach Langzeitdialyse. Klin Wochenschr 1984; 62: 862–6PubMedCrossRef

15.

Jesch F, Hübner G, Zumtobel V, et al. Hydroxyäthylstärke (HÄS 450/0,7) in Plasma und Leber-Konzentrationsverlauf und histologische Veränderungen beim Menschen. Infusionsther Klin Ernahr 1979; 6: 112–7PubMed

16.

Ständer S, Bone HG, Machens HG, et al. Hydroxyethyl starch does not cross the blood-brain or the placental barrier but the perineurium of peripheral nerves in infused animals. Cell Tissue Res 2002; 310: 279–87PubMedCrossRef

17.

Metze D, Reimann S, Szepfalusi Z, et al. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. Br J Dermatol 1997; 136: 553–9PubMedCrossRef

18.

Cox NH, Popple AW. Persistent erythema and pruritus, with a confluent histiocytic skin infiltrate, following the use of a hydroxyethylstarch plasma expander. Br J Dermatol 1996; 134: 353–7PubMedCrossRef

19.

Jurecka W, Szepfalusi Z, Parth E, et al. Hydroxyethylstarch deposits in human skin: a model for pruritus? Arch Dermatol Res 1993; 285: 13–9PubMedCrossRef

20.

Heilmann L, Lorch E, Hojnacki B, et al. Die Speicherung von zwei unterschiedlichen Hydroxyäthylstärke-Präparaten in der Plazenta nach Hämodilution bei Patientinnen mit fetaler Mangelentwicklung oder Schwangerschaftshochdrucks. Infusionstherapie 1991; 18: 236–43PubMed

21.

Van Rijen EA, Ward JJ, Little RA. Effects of colloidal resuscitation fluids on reticuloendothelial function and resistance to infection after hemorrhage. Clin Diagn Lab Immunol 1998; 5: 543–9PubMed

22.

Shatney CH, Chaudry IH. Hydroxyethylstarch administration does not depress reticuloendothelial function or increase mortality from sepsis. Circ Shock 1984; 13: 21–6PubMed

23.

Ginz H, Gottschall V, Schwarzkopf G, et al. Exzessive Gewebespeicherung von Kolloiden im retikuloendothelialen System. Anaesthesist 1998; 47: 330–4PubMedCrossRef

24.

Gröchenig E, Albegger K, Dieterich HJ, et al. Hydroxyethyl-starch-related pruritus: a prospective multicentre investigation of 544 patients. Perfusion 1998; 11: 62–9

25.

Speight EL, MacSween RM, Stevens A. Persistent itching due to etherified starch plasma expander. BMJ 1997; 314: 1466–7PubMedCrossRef

26.

Neff TA, Doelberg M, Jungheinrich C, et al. Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anest Analg 2003; 96: 1453–9CrossRef

27.

Rudolf J. Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: a randomized, placebo-controlled phase II safety study. Cerebrovasc Dis 2002; 14: 33–41PubMedCrossRef

28.

Grauer MT, Baus D, Woessner R, et al. Effects on general safety and coagulation after long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 in patients with acute ischemic stroke: results of a randomised, placebo-controlled, double-blind study [abstract]. Crit Care 2001; 5 Suppl. 1: P115CrossRef

Titel: Tissue Storage of 14C-Labelled Hydroxyethyl Starch (HES) 130/0.4 and HES 200/0.5 after Repeated Intravenous Administration to Rats
verfasst von: Jost Leuschner
Jens Opitz
Andreas Winkler
Roland Scharpf
Dr Frank Bepperling
Publikationsdatum: 01.11.2003
Verlag: Springer International Publishing
Erschienen in: Drugs in R&D / Ausgabe 6/2003
Print ISSN: 1174-5886
Elektronische ISSN: 1179-6901
DOI: https://doi.org/10.2165/00126839-200304060-00001

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Tissue Storage of ¹⁴C-Labelled Hydroxyethyl Starch (HES) 130/0.4 and HES 200/0.5 after Repeated Intravenous Administration to Rats

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2003

Lobaplatin

SR 58611A

Xemilofiban

Diquafosol

Staphylococcus aureus Vaccine Conjugate — Nabi

Petasites — Zeller